#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

The importance of diet therapy and the correct regimen in familial hypercholesterolemia


Authors: Věra Boháčová;  Tamara Starnovská
Authors‘ workplace: Fórum zdravé výživy, Sekce výživy a nutriční péče, z. s., Praha
Published in: AtheroRev 2022; 7(3): 152-155
Category: Reviews

Overview

As part of influencing the lipid spectrum, lifestyle modification is attributed to the possibility of lowering LDL by 10–15%, which may be more or less sufficient as part of the therapy. In the case of patients with familial hypercholesterolemia, modification of the regimen alone is not sufficient. Even so, it is important to follow the professional recommendations regarding the regimen. By adjusting the diet and overall lifestyle, in addition to the lipid spectrum, other factors that contribute to the overall risk of the disease are also affected. This can lead to an overall better prognosis for patients and an increase in their quality of life.

Keywords:

Diet – dyslipidemia – risk factors – familial hypercholesterolemia – regimen


Sources

1. Børge G, Nordestgaard, M, Chapman J et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease – Consensus Statement of the European Atherosclerosis Society. Eur Heart J 2013; 34(45): 3478–3490a. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/eht273>.

2. Mach F, Baigentb C, Catapano AL et al. [Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies]. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis 2019; 290: 140–205. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2019.08.014>. Erratum in Atherosclerosis 2020; 292: 160–162. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2019.11.020>.

3. Hegele RA, Borén J, Ginsberg HN et al. Vzácné dyslipidemie, od fenotypu ke genotypu a léčbě: konsensus pracovní skupiny Evropské společnosti pro aterosklerózu (česká jazyková verze připravena a garantována Českou společností pro aterosklerózu, o. s.). AtheroRev 2021; 6(S1): 3–18.

4. Soška V. Poruchy metabolizmu lipidů: Nefarmakologická léčba DLP (7.2). Grada: Praha 2001. ISBN 80–247–02347.

5. Boháčová V, Vrablík M. Výživa v prevenci a léčbě poruch metabolismu tuků. In: Kohout P (ed). Klinická výživa. Galén: Praha 2021. ISBN 97880–7492–555–9.

6. Kraml P. Hyperlipoproteinémie v klinické praxi: Obecné dietní a režimové zásady (4.1). Tigis: Praha 2008. ISBN 978–80–903750–5-5.

7. Tuka V, Křečková M. Pohyb – pohybová aktivita při vysokém cholesterolu a familiární hypercholesterolémii. Diganóza FH. Dostupné z WWW: <https://diagnozafh.cz/wp-content/uploads/2021/12/pohyb_brozura_210x210_v06.pdf>.

8. Barkas F, Nomikos T, Liberopoulos E et al. Diet and Cardiovascular Disease Risk Among Individuals with Familial Hypercholesterolemia: Systematic Review and Meta-Analysis. Nutrients 2020; 12(8): 2436. Dostupné z DOI: <http://dx.doi.org/10.3390/nu12082436>.

Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adults
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#